AI Article Synopsis
- Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive type of cancer in children that combines elements of myelodysplastic syndrome and myeloproliferative neoplasm.
- Traditional chemotherapy is largely ineffective for treating JMML, making hematopoietic stem cell transplantation the only viable cure currently available.
- Recent advancements in targeted therapies, particularly focusing on mutations in the Ras signaling pathway and demethylation treatment for certain genetic abnormalities, have shown promise in improving treatment outcomes.
Article Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare chronic myeloid leukemia in children and has the features of both myelodysplastic syndrome and myeloproliferative neoplasm. It is highly malignant and has a poor treatment outcome. Children with JMML have a poor response to conventional chemotherapy. At present, hematopoietic stem cell transplantation is the only possible cure for this disease. In recent years, significant progress has been made in targeted therapy for mutant genes in the Ras signaling pathway and demethylation treatment of aberrant methylation of polygenic CpG islands. This article reviews the treatment and efficacy evaluation of JMML.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389026 | PMC |
| http://dx.doi.org/10.7499/j.issn.1008-8830.2018.11.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!